尿激酶联合丹参酮IIA治疗脑血栓形成80例分析  

The value for the clinical application of urokinase combined with sodium tanshinon IIA in the treatment of cerebral thrombosis

作　　者：孟宪良[1] 孔令华[1] 朱爱萍[1] 

机构地区：[1]滨州市中心医院一结防院神经内科二病区,山东省滨州251700

出　　处：《中国基层医药》2012年第7期985-986,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨尿激酶联合丹参酮IIA在脑血栓形成治疗中的临床应用价值。方法脑血栓形成患者160例，随机分为观察组（尿激酶联合丹参酮IIA治疗组）、对照组（尿激酶治疗组）各80例，2周为1疗程。治疗结束时对两组患者进行临床疗效统计分析。结果经治疗，两组患者神经功能缺损情况均得到明显改善（P〈0．05）；观察组患者治疗后神经功能缺损评分明显低于对照组（P〈0．05）；观察组患者经尿激酶与丹参酮IIA联合治疗总有效率为95％明显高于对照组（尿激酶治疗组）的71％（P〈0．05）。结论尿激酶联合丹参酮IIA治疗脑血栓形成能有效改善患者神经功能缺损情况，提高患者临床治疗效果。Objective To investigate the value for the clinical application of urokinase combined with Sodi- um Tanshion IIA in the treatment of cerebral thrombosis. Methods 160 cases with cerebral thrombosis in our hospital were chosen. They were randomly divided into A group with 80 cases and B group with 80 cases. A group was the observation group（Tanshion IIA Urokinase combined treatment group）, B group was the control group （urine kinase treatment group）. 2 weeks treatment was a course. The efficacy of treatment in the two groups at the end was taken for statistical analysis. Results The neurological deficits were significantly improved in A and B group before and after treatment（ P 〈 0.05, there was statistically significant）. The neurological deficit scores in A group after treatment was significantly lower than group B （P 〈 0.05, there was statistically significant）. The total effective rate was 95% by the treatment of urokinase and Tanshion IIA in A group which was higher than group B （ P 〈 0.05, there was statistically significant difference）. Conclusion The treatment of urokinase combined with Sodium Tanshion IIA could improve neurological deficits and improve the clinical therapeutic effect.

关 键 词：颅内血栓形成 尿纤溶酶原激活物 丹参酮 

分 类 号：R743[医药卫生—神经病学与精神病学]